Back

Time-to-benefit of glucagon-like peptide-1 receptor agonists for cardiovascular protection in type 2 diabetes

31 August 2026 (08:15 - 08:27)
Organised by: Logo
Congress Presentation Part of: Secondary prevention strategies in coronary artery disease Secondary Prevention ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Miss Chih Jung Chang

Fu Jen Catholic University, New Taipei (Taiwan)

4 More presentations in this session

Presentation thumbnail
SELECT in the light of FAST-MI. Potential population-based benefit of semaglutide 2.4mg/week on mortality, an extrapolation from the SELECT trial results to the FAST-MI registries.
Professor F. Schiele (Besancon, FR)
Abstract
Presentation thumbnail
Beta-blocker therapy and all-cause mortality after percutaneous coronary intervention: a state-wide propensity score matched analysis stratified by left ventricular ejection fraction
Mrs P. Cataldo Miranda (Melbourne, AU)
Abstract
Presentation thumbnail
Distinct phenotype of very early-onset coronary artery disease (≤35 years): baseline findings from a multicentre prospective cohort
Miss X. Ding (Beijing, CN)
Abstract
Presentation thumbnail
Beyond the genome: the dominant role of biological age over polygenic risk in post-PCI mortality prediction.
Miss M. Liu (Beijing, CN)
Abstract

Access the full session

Session thumbnail
Secondary prevention strategies in coronary artery disease

The Event

Event poster

ESC Congress 2026

31 August 2026 08:15 CET
You may be interested in
thumbnail
Congress Presentation
Timing of statistical benefit of canagliflozin in patients with type 2 diabetes for cardiovascular and heart failure outcomes: insights from the CANVAS Program and CREDENCE trial
20 May 2023
thumbnail
ESC Journals
Glucagon-like peptide-1 increases heart rate by a direct action on the sinus node
4 June 2024
thumbnail
Congress Presentation
GLP-1 receptor agonists as an opportunity for patients with atherosclerotic cardiovascular disease as well as obesity in Germany
1 September 2025
thumbnail
Congress Presentation
LDL treatment-years: a new paradigm for cardiovascular risk reduction
1 September 2025

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources